Hycamtin Of Value In NSCLC
SmithKline Beecham's topoisomerase I inhibitor Hycamtin (topotecanhydrochloride) may be a promising new treatment option for advanced squamous cell lung cancer, a subtype of non-small cell lung cancer. The drug is currently indicated for the treatment of recurrent, metastatic ovarian cancer.
The results of a non-comparative Phase II trial of Hycamtin in 30 patients with NSCLC suggest that the drug achieved an overall response rate of 23%. The overall median survival was 44 weeks, which compares favorably with the survival times seen with other first-line therapies.
There is a desperate lack of therapies for patients with NSCLC. Studies are now underway looking at using Hycamtin in combination with other drugs or radiotherapy. The drug has also shown promise in the treatment of small cell lung cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze